ISIS PHARMACEUTICAL
ISIS PHARMACEUTICAL operates in Diversified Metals & Mining.
ISIS PHARMACEUTICAL (ISI) - Total Assets
Latest total assets as of September 2024: €3.08 Billion EUR
Based on the latest financial reports, ISIS PHARMACEUTICAL (ISI) holds total assets worth €3.08 Billion EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ISIS PHARMACEUTICAL - Total Assets Trend (2016–2023)
This chart illustrates how ISIS PHARMACEUTICAL’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ISIS PHARMACEUTICAL - Asset Composition Analysis
Current Asset Composition (December 2023)
ISIS PHARMACEUTICAL's total assets of €3.08 Billion consist of 88.4% current assets and 11.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €28.43 Million | 1.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how ISIS PHARMACEUTICAL's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ISIS PHARMACEUTICAL's current assets represent 88.4% of total assets in 2023, an increase from 87.5% in 2016.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2023, up from 9.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 1.0% of total assets.
ISIS PHARMACEUTICAL Competitors by Total Assets
Key competitors of ISIS PHARMACEUTICAL based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
ISIS PHARMACEUTICAL - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ISIS PHARMACEUTICAL generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ISIS PHARMACEUTICAL is currently not profitable relative to its asset base.
ISIS PHARMACEUTICAL - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.91 | 6.39 | 9.97 |
| Quick Ratio | 8.82 | 6.33 | 9.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.41 Billion | € 2.18 Billion | € 2.45 Billion |
ISIS PHARMACEUTICAL - Advanced Valuation Insights
This section examines the relationship between ISIS PHARMACEUTICAL's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 18.0% |
| Total Assets | €2.99 Billion |
| Market Capitalization | $638.61K USD |
Valuation Analysis
Below Book Valuation: The market values ISIS PHARMACEUTICAL's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ISIS PHARMACEUTICAL's assets grew by 18.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ISIS PHARMACEUTICAL (2016–2023)
The table below shows the annual total assets of ISIS PHARMACEUTICAL from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €2.99 Billion | +18.00% |
| 2022-12-31 | €2.53 Billion | -2.98% |
| 2021-12-31 | €2.61 Billion | +9.29% |
| 2020-12-31 | €2.39 Billion | -26.08% |
| 2019-12-31 | €3.23 Billion | +21.19% |
| 2018-12-31 | €2.67 Billion | +101.80% |
| 2017-12-31 | €1.32 Billion | +44.88% |
| 2016-12-31 | €912.47 Million | -- |